The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Patients with breast cancer whose tumors test positive for human epidermal growth factor receptor 2 (HER2) are treated with HER2-targeted therapies such as trastuzumab, but limitations with HER2 testing may lead to false-positive (FP) or false-negative (FN) results.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Value Health

Title: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Publisher: Elsevier BV

ISSN (Electronic): 1524-4733

ISSN (Print): 1098-3015

Publication date (Electronic): Jun 2015

Volume: 18

Issue: 4

Affiliations

[1 ] VeriTech Corporation, Mercer Island, WA, USA; University of Washington, Seattle, WA, USA. Electronic address: lgarrisn@u.washington.edu.

[2 ] VeriTech Corporation, Mercer Island, WA, USA; University of Washington, Seattle, WA, USA.

[3 ] Genentech, Inc., South San Francisco, CA, USA.

[4 ] Alliance Life Sciences, Somerset, NJ, USA.

Article

Publisher Item ID: S1098-3015(15)01918-X

DOI: 10.1016/j.jval.2015.01.012

PubMed ID: 26091608

SO-VID: 6562bf94-e751-4d5e-b819-f15a8d2a469a

History

Keywords: trastuzumab,HER2 testing,breast cancer,economic burden

Data availability:

Keywords: trastuzumab, HER2 testing, breast cancer, economic burden

Comments

Comment on this article

scite_

Cited by 6

See all cited by

- Version 1